Biomedical subjects

J Vamecq

Publications and source records attributed to J Vamecq.

77 records · Page 5Linked to original sources

PubMedDate not supplied

In vivo hydrogen peroxide production in rat remnant kidney.

In the rat remnant kidney hydrogen peroxide (H2O2) production is increased when compared to the normal kidney. The activities of the peroxisomal H2O2-producing oxidases, D-amino acid oxidase and acyl-coenzyme A oxidase, and of the extraperoxisomal superoxide dismutase are decreased in renal homogenate. The peroxisomal L-alpha-hydroxyacid oxidase and L-lactate oxidase as well as the peroxisomal H2O2 scavenger catalase preserve their activity. The activity of the cytosolic scavenging system, glutathione peroxidase, is decreased by 40%. A starvation period of 48 h does not produce a measurable increase in H2O2 production in the normal nor in the remnant kidney. On visual inspection, peroxisomal morphology and distribution in the renal tubules are similar in the normal and remnant kidney tissue.

Amitrole↗

PubMedDate not supplied

Are physiological clonal expansion and maturation pathways a basis for discrepant behaviour of colon tumoral cell growth in response to the thiazolidinedione PPARgamma agonists?

Recently, anti-diabetic thiazolidinediones, pharmacological agonist ligands of peroxisome proliferator-activated receptor gamma (PPARgamma), have been shown to induce either protective or permissive effects towards colon epithelium tumoral cell growth. Several attractive explanations have been proposed but no final answer to these is currently provided. It is not the purpose of the authors to bring this final answer but to offer another attractive hypothesis which might help our approach to explore further this exciting field of medical research.

Cell Differentiation↗

PubMedDate not supplied

[Metabolic treatment of cancer].

The aim of the metabolic therapy of cancer is to cure the disease by interfering with metabolism, and not with, as is the case in classical chemotherapy, the genotype of the cancer cell. Current advance and perspective in this novel topic are here presented.

Animals↗

PubMedDate not supplied

[Cerebral venous thrombosis disclosing Behçet disease].

BACKGROUND: Behçet's disease is very occasionally revealed by thrombophlebitis in children. Dural sinus thrombosis can be one of its complication. CASE REPORT: A 14 year-old boy of Mediterranean origin was admitted for acute meningitis with temperature of 40 degrees C. His CSF contained 24 cells/ml and 0.33 g/l protein; it was sterile. The RBC sedimentation rate was 84 mm. Other investigations, including brain scan, were negative. The condition became worse, with a deterioration of visual acuity, attack of aphthous stomatitis and skin lesions at points of puncture. There was papilledema with retinal vascularitis. A second brain scan and MRI showed sagittal sinus thrombosis. The condition improved immediately after treatment with prednisolone and ticlopidine. The brain MRI taken 3 months later showed partial permeability of the sagittal sinus. The patient had several attacks of meningoencephalitis and stomatitis during the following 2 years. The last attack was complicated by iridocyclitis; this required cyclosporin treatment. CONCLUSION: Phlebothrombosis is a classic complication of Behçet's disease and can reveal the disease. Sagittal sinus thrombosis has never before been reported as the first manifestation of the disease in children.

Adolescent↗

PubMedDate not supplied

[Rational conception, synthesis and evaluation of phenytoinergic potential anticonvulsants. A series ofretrobenzamides: N-(nitrophenyl) benzamides and N-(aminophenyl) benzamides].

Retrobenzamides [N-(nitrophenyl) benzamides and N-(aminophenyl)benzamides] were developed in the perpective of a design for phenytoinergic agents. Anticonvulsant and neurotoxic properties of these compounds were evaluated in mice and rats in two seizure models (maximal electroshock-induced seizures [MES] and seizures induced by subcutaneous administration of pentylenetetrazole [scPtz]) and in the rotorod test. Data obtained were compared with those recorded on carbamazepine and phenytoin (antiepileptic drugs widely utilized in human clinics), ameltolide (anticonvulsant compound recently developed by Eli Lilly in human clinical trials) and other compounds previously reported by our research group. Studies on retrobenzamides in mice administered by intraperitoneal route point out a good anticonvulsant potential in the MES test for the amino derivatives (N-(aminophenyl)benzamides) and moderate activity in the case of the corresponding "nitro" derivatives. In rats dosed orally, aminoretrobenzamides were less active in the MES test than in mice dosed intraperitoneally.

Animals↗